Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Dolutegravir, ATC J05AJ03 für die Zeit 01.06.2026 - 31.05.2028

Section 130a Paragraph 8 SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount agreements for medicines to be dispensed at the expense of the statutory health insurance companies. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts active substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For the medicines to be specified by the bidder in more detail in Annex 2 to the contract, relating to the above-mentioned active substance Dolutegravir, ATC J05AJ03, the DAK-Gesundheit intends to conclude medicines discount agreements with as many interested pharmaceutical companies as possible until the entry into force of new medicines discount agreements. A discount agreement under the approval model for the above-mentioned active substance will come into force for the first time on 01.06.2026 and will end on 31.05.2028. It will automatically end, regardless of this, with the entry into force of the exclusive agreement.